fashion -WSS

fashion

author：hotspot 2025-09-06 03:55:31 - browse：8611

The Chamber of Commerce in downtown Washington, DC. — The U.S. Chamber of Commerce sued to stop a new Medicare drug price negotiation program from going into effect. Adobe

WASHINGTON — Attorneys for the U.S. Chamber of Commerce and the federal government sparred Friday over whether drugmakers have enough say in Medicare’s new drug price negotiation program, in the first oral arguments in a lawsuit challenging the new law.

The two sides debated two questions: whether the Chamber of Commerce would be sufficiently injured by the law to file a lawsuit, and whether the negotiation program was a violation of drugmakers’ due process rights.

The hearing was held in the U.S. District Court for the Southern District of Ohio, and Judge Michael Newman, a Trump nominee, presided. Newman didn’t ask any questions of the attorneys, so the hearing didn’t provide any hints about which way he might be leaning on the issues.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Biogen nominates mother of director’s child to replace him on board

WSS

How to fix the rural physician shortage in the U.S.

Cigna, Humana reportedly in talks to merge

U.K. Biobank has 500,000 peoples' genome sequences available

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Wikipedia

fashion

Wikipedia

Supreme Court strikes down use of affirmative action

UnitedHealth’s Optum accused of antitrust violations in California

Alkermes shareholders re

Inside the rise of 'mukbang' eating videos

Peter Hotez and the public health issue of online harassment

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

At least 13 dead in Texas as scorching temps continue

Flagship Pioneering launches a new biotech in two countries

Heart attack and stroke risk calculators need revising

Despite FDA concern, risk that CAR

entertainment

Will the market for weight loss drugs really reach $100 billion?

BIO selects John Crowley as new CEO

FDA approves first new drug developed for postpartum depression

Senate panel passes drug pricing bills, but drops one PBM reform

Organ aging and disease risk measured by new blood test

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

focus

leisure time

focus

hotspot